Study Graphic

You may be eligible if:

  • You are a healthy male or female between the ages of 18 and 55 at the time of screening.
  • You are able to meet all eligibility criteria.
  • You are able to comply with all study visits.

Study number: B3491017

  • You will be paid $175.00 for travel expenses to and from screening
  • You will be compensated up to $1,850.00 for completion of the study

The Pfizer New Haven Clinical Research Unit is conducting a study of a marketed over-the-counter drug approved by the United States Food and Drug Administration (FDA). It is used to manage pain and fever. The study drug will be given as a tablet, which you will swallow.

This study involves:

You will be in this study up to about 23 days. This does not include the time between screening and dosing, which can be up to 28 days.

This study involves:

  • 3 dosing periods (during one continuous admission)
  • 6 overnight stays
  • 1 follow-up phone call (14 to 17 days after the last dose)There will be at least 2 days between each dose.

Please review the Informed Consent Document: B3491017 ICD v 11OCT2018

Please review more information about the study: B3491017_Guidelines-Restriction-Dates_26Sep2018_G1